A Phase 2 interventional study of Olpasiran and Placebo in Cardiovascular Disease, sponsored by Amgen. Completed at 36 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]).
5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.
This study's enrollment of 281 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Olpasiran
Drug: Olpasiran
Drug: Olpasiran
Drug: Olpasiran
Drug: Placebo
Dose 1 Dose 2 Dose 3 Dose 4
Also known as: AMG 890
Dose 5
Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.
Time frame: Baseline and Week 36
Percentage Change From Baseline in Lp(a) at Week 48
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.
Time frame: Baseline and Week 48
Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 36 and Week 48
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.
Time frame: Baseline; Week 36 and Week 48
Percentage Change From Baseline in Apolipoprotein (B) (ApoB) at Week 36 and Week 48
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.
Time frame: Baseline; Week 36 and Week 48
Mean Serum Olpasiran Concentrations at Day 1, Week 24 and Week 48
Pharmacokinetic blood draws were collected at one timepoint during the 6-12 and 24-72 hour flexible time windows and at Week 48. Lower limit of quantification (LLOQ) = 0.400 ng/mL. Values below the LLOQ were set to zero.
Time frame: Pre-dose and 1, 3, 6-12, and 24-72 hours post-dose on Day 1 and Week 24; Week 48
This study was conducted at 34 centers in Australia, Denmark, Iceland, the Netherlands, Canada, the United States, and Japan between 28 July 2020 and 08 November 2022.
| Milestone | Group 1: Olpasiran 10 mg Q12W | Group 2: Olpasiran 75 mg Q12W | Group 3: Olpasiran 225 mg Q12W | Group 4: Olpasiran 225 mg Q24W | Group 5: Placebo Q12W |
|---|---|---|---|---|---|
| Started | 58 | 58 | 56 | 55 | 54 |
| Entered extended safety follow-up period | 57 | 57 | 54 | 55 | 53 |
| Completed | 57 | 55 | 52 | 55 | 53 |
| Not completed | 1 | 3 | 4 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.
| Percentage Change in Lp(a) | Group 1: Olpasiran 10 mg Q12W | Group 2: Olpasiran 75 mg Q12W | Group 3: Olpasiran 225 mg Q12W | Group 4: Olpasiran 225 mg Q24W | Group 5: Placebo Q12W |
|---|---|---|---|---|---|
| Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 | -66.91 ± 1.78 | -93.78 ± 1.78 | -97.53 ± 1.82 | -96.89 ± 1.85 | 3.60 ± 1.89 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.
| Percentage Change in Lp(a) | Group 1: Olpasiran 10 mg Q12W | Group 2: Olpasiran 75 mg Q12W | Group 3: Olpasiran 225 mg Q12W | Group 4: Olpasiran 225 mg Q24W | Group 5: Placebo Q12W |
|---|---|---|---|---|---|
| Percentage Change From Baseline in Lp(a) at Week 48 | -64.89 ± 2.17 | -92.54 ± 2.17 | -97.29 ± 2.22 | -82.36 ± 2.25 | 3.59 ± 2.30 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.
| Percentage Change in LDL-C | Group 1: Olpasiran 10 mg Q12W | Group 2: Olpasiran 75 mg Q12W | Group 3: Olpasiran 225 mg Q12W | Group 4: Olpasiran 225 mg Q24W | Group 5: Placebo Q12W |
|---|---|---|---|---|---|
| Week 36 | -17.425 ± 4.258 | -16.284 ± 4.259 | -16.733 ± 4.389 | -18.462 ± 4.428 | 6.234 ± 4.520 |
| Week 48 | -14.743 ± 4.419 | -11.481 ± 4.418 | -17.308 ± 4.532 | -16.908 ± 4.608 | 10.113 ± 4.688 |
Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.
| Percentage Change in ApoB | Group 1: Olpasiran 10 mg Q12W | Group 2: Olpasiran 75 mg Q12W | Group 3: Olpasiran 225 mg Q12W | Group 4: Olpasiran 225 mg Q24W | Group 5: Placebo Q12W |
|---|---|---|---|---|---|
| Week 36 | -11.496 ± 2.886 | -9.302 ± 2.885 | -10.241 ± 2.960 | -11.378 ± 3.012 | 7.394 ± 3.066 |
| Week 48 | -7.748 ± 3.307 | -4.768 ± 3.305 | -7.218 ± 3.393 | -9.548 ± 3.443 | 12.292 ± 3.501 |
Pharmacokinetic blood draws were collected at one timepoint during the 6-12 and 24-72 hour flexible time windows and at Week 48. Lower limit of quantification (LLOQ) = 0.400 ng/mL. Values below the LLOQ were set to zero.
| ng/mL | Group 1: Olpasiran 10 mg Q12W | Group 2: Olpasiran 75 mg Q12W | Group 3: Olpasiran 225 mg Q12W | Group 4: Olpasiran 225 mg Q24W |
|---|---|---|---|---|
| Day 1: Pre-dose | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 1: 1 Hour Post-dose | 12.3 ± 6.9 | 67.1 ± 47.4 | 220 ± 218 | 275 ± 450 |
| Day 1: 3 Hours Post-dose | 18 ± 9.85 | 80.3 ± 43.2 | 291 ± 273 | 324 ± 383 |
| Day 1: 6-12 Hours Post-dose | 18.6 ± 10.1 | 61.7 ± 36 | 420 ± 432 | 329 ± 191 |
| Day 1: 24-72 Hours Post-dose | 0.995 ± 0.946 | 20.4 ± 13.2 | 63.2 ± 59.7 | 103 ± 47.3 |
| Week 24: Pre-dose | 0.00 ± 0.00 | 0.0315 ± 0.134 | 0.498 ± 1.88 | 0.0645 ± 0.22 |
| Week 24: 1 Hour Post-dose | 12.4 ± 7.23 | 73.6 ± 43.6 | 204 ± 144 | 253 ± 247 |
| Week 24: 3 Hours Post-dose | 16.3 ± 9.2 | 96.3 ± 63.5 | 278 ± 193 | 332 ± 255 |
| Week 24: 6-12 Hours Post-dose | 17.2 ± 10.2 | 76.3 ± 54.7 | 271 ± 229 | 315 ± 191 |
| Week 24: 24-72 Hours Post-dose | 1.27 ± 1.82 | 17.3 ± 18.9 | 99 ± 59.1 | 96.3 ± 50.3 |
| Week 48 | 0.00 ± 0.00 | 0.0599 ± 0.168 | 0.533 ± 0.592 | 0.127 ± 0.693 |
Collected over Treatment Period: Median duration was 11.07 months. Extended Safety Follow-up Period: Median duration was 8.56 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1; Treatment Period: Olpasiran 10 mg Q12W | 0/58 (0%) | 3/58 (5.2%) | 35/58 (60.3%) |
| Group 2; Treatment Period: Olpasiran 75 mg Q12W | 0/58 (0%) | 3/58 (5.2%) | 40/58 (69%) |
| Group 3; Treatment Period: Olpasiran 225 mg Q12W | 0/56 (0%) | 6/56 (10.7%) | 37/56 (66.1%) |
| Group 4; Treatment Period: Olpasiran 225 mg Q24W | 0/55 (0%) | 4/55 (7.3%) | 36/55 (65.5%) |
| Group 5; Treatment Period: Placebo Q12W | 1/54 (1.9%) | 8/54 (14.8%) | 29/54 (53.7%) |
| Group 1; Extended Safety Follow-up Period: Olpasiran 10 mg Q12W | 0/57 (0%) | 4/57 (7%) | 18/57 (31.6%) |
| Group 2; Extended Safety Follow-up Period: Olpasiran 75 mg Q12W | 0/57 (0%) | 2/57 (3.5%) | 25/57 (43.9%) |
| Group 3; Extended Safety Follow-up Period: Olpasiran 225 mg Q12W | 0/54 (0%) | 6/54 (11.1%) | 21/54 (38.9%) |
| Group 4; Extended Safety Follow-up Period: Olpasiran 225 mg Q24W | 0/55 (0%) | 5/55 (9.1%) | 17/55 (30.9%) |
| Group 5; Extended Safety Follow-up: Placebo Q12W | 0/53 (0%) | 4/53 (7.5%) | 17/53 (32.1%) |
| Event | Group 1; Treatment Period: Olpasiran 10 mg Q12W | Group 2; Treatment Period: Olpasiran 75 mg Q12W | Group 3; Treatment Period: Olpasiran 225 mg Q12W | Group 4; Treatment Period: Olpasiran 225 mg Q24W | Group 5; Treatment Period: Placebo Q12W | Group 1; Extended Safety Follow-up Period: Olpasiran 10 mg Q12W | Group 2; Extended Safety Follow-up Period: Olpasiran 75 mg Q12W | Group 3; Extended Safety Follow-up Period: Olpasiran 225 mg Q12W | Group 4; Extended Safety Follow-up Period: Olpasiran 225 mg Q24W | Group 5; Extended Safety Follow-up: Placebo Q12W |
|---|---|---|---|---|---|---|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/58 | 0/58 | 1/56 | 0/55 | 0/54 | 0/57 | 0/57 | 2/54 | 0/55 | 0/53 |
| CholangitisHepatobiliary disorders | 0/58 | 0/58 | 0/56 | 0/55 | 0/54 | 0/57 | 0/57 | 0/54 | 0/55 | 1/53 |
| Cervical spinal stenosisMusculoskeletal and connective tissue disorders | 0/58 | 0/58 | 0/56 | 0/55 | 0/54 | 0/57 | 0/57 | 0/54 | 0/55 | 1/53 |
| Gastrointestinal cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/58 | 0/58 | 0/56 | 0/55 | 0/54 | 0/57 | 0/57 | 0/54 | 0/55 | 1/53 |
| Metastases to pancreasNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/58 | 0/58 | 0/56 | 0/55 | 0/54 | 0/57 | 0/57 | 0/54 | 0/55 | 1/53 |
| Ischaemic strokeNervous system disorders | 0/58 | 0/58 | 0/56 | 0/55 | 0/54 | 0/57 | 0/57 | 0/54 | 0/55 | 1/53 |
| Angina pectorisCardiac disorders | 0/58 | 0/58 | 0/56 | 0/55 | 1/54 | 1/57 | 0/57 | 0/54 | 0/55 | 0/53 |
| Angina unstableCardiac disorders | 1/58 | 0/58 | 1/56 | 0/55 | 1/54 | 0/57 | 0/57 | 0/54 | 0/55 | 0/53 |
| Rectal haemorrhageGastrointestinal disorders | 0/58 | 0/58 | 0/56 | 0/55 | 0/54 | 0/57 | 0/57 | 1/54 | 0/55 | 0/53 |
| Non-cardiac chest painGeneral disorders | 0/58 | 0/58 | 0/56 | 0/55 | 1/54 | 0/57 | 0/57 | 0/54 | 0/55 | 0/53 |
| Event | Group 1; Treatment Period: Olpasiran 10 mg Q12W | Group 2; Treatment Period: Olpasiran 75 mg Q12W | Group 3; Treatment Period: Olpasiran 225 mg Q12W | Group 4; Treatment Period: Olpasiran 225 mg Q24W | Group 5; Treatment Period: Placebo Q12W | Group 1; Extended Safety Follow-up Period: Olpasiran 10 mg Q12W | Group 2; Extended Safety Follow-up Period: Olpasiran 75 mg Q12W | Group 3; Extended Safety Follow-up Period: Olpasiran 225 mg Q12W | Group 4; Extended Safety Follow-up Period: Olpasiran 225 mg Q24W | Group 5; Extended Safety Follow-up: Placebo Q12W |
|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 1/58 | 8/58 | 7/56 | 4/55 | 6/54 | 8/57 | 11/57 | 14/54 | 10/55 | 10/53 |
| FatigueGeneral disorders | 6/58 | 8/58 | 3/56 | 2/55 | 3/54 | 2/57 | 1/57 | 0/54 | 0/55 | 1/53 |
| Immunisation reactionImmune system disorders | 8/58 | 4/58 | 2/56 | 4/55 | 5/54 | 0/57 | 0/57 | 2/54 | 0/55 | 0/53 |
| Back painMusculoskeletal and connective tissue disorders | 6/58 | 5/58 | 7/56 | 1/55 | 3/54 | 3/57 | 1/57 | 1/54 | 1/55 | 0/53 |
| HeadacheNervous system disorders | 6/58 | 7/58 | 6/56 | 6/55 | 4/54 | 0/57 | 1/57 | 2/54 | 1/55 | 0/53 |
| Injection site painGeneral disorders | 2/58 | 3/58 | 1/56 | 5/55 | 2/54 | 0/57 | 0/57 | 0/54 | 0/55 | 0/53 |
| Injection site bruisingGeneral disorders | 0/58 | 4/58 | 5/56 | 0/55 | 4/54 | 0/57 | 0/57 | 0/54 | 0/55 | 0/53 |
| DiarrhoeaGastrointestinal disorders | 2/58 | 3/58 | 3/56 | 1/55 | 4/54 | 0/57 | 0/57 | 0/54 | 1/55 | 0/53 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/58 | 1/58 | 4/56 | 4/55 | 4/54 | 2/57 | 0/57 | 0/54 | 0/55 | 0/53 |
| Injection site erythemaGeneral disorders | 0/58 | 3/58 | 3/56 | 4/55 | 0/54 | 0/57 | 0/57 | 0/54 | 0/55 | 0/53 |
Full Analysis Set (FAS): includes all randomized participants who received at least one dose of IP.
| Age, Continuous(Years) | Group 1: Olpasiran 10 mg Q12W | Group 2: Olpasiran 75 mg Q12W | Group 3: Olpasiran 225 mg Q12W | Group 4: Olpasiran 225 mg Q24W | Group 5: Placebo Q12W | Total |
|---|---|---|---|---|---|---|
| Mean | 63.4 ± 9.5 | 61.3 ± 9.2 | 59.7 ± 10.1 | 61.8 ± 9.4 | 63.4 ± 8.9 | 61.9 ± 9.5 |
| Age, Customized(Participants) | Group 1: Olpasiran 10 mg Q12W | Group 2: Olpasiran 75 mg Q12W | Group 3: Olpasiran 225 mg Q12W | Group 4: Olpasiran 225 mg Q24W | Group 5: Placebo Q12W | Total |
|---|---|---|---|---|---|---|
| 18 - 64 years | 31 | 35 | 37 | 31 | 29 | 163 |
| 65 - 74 years | 19 | 17 | 18 | 19 | 17 | 90 |
| 75 - 84 years | 8 | 6 | 1 | 5 | 8 | 28 |
| Sex: Female, Male(Participants) | Group 1: Olpasiran 10 mg Q12W | Group 2: Olpasiran 75 mg Q12W | Group 3: Olpasiran 225 mg Q12W | Group 4: Olpasiran 225 mg Q24W | Group 5: Placebo Q12W | Total |
|---|---|---|---|---|---|---|
| Female | 12 | 23 | 15 | 22 | 18 | 90 |
| Male | 46 | 35 | 41 | 33 | 36 | 191 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Olpasiran 10 mg Q12W | Group 2: Olpasiran 75 mg Q12W | Group 3: Olpasiran 225 mg Q12W | Group 4: Olpasiran 225 mg Q24W | Group 5: Placebo Q12W | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 0 | 2 | 2 | 6 |
| Not Hispanic or Latino | 56 | 58 | 56 | 53 | 52 | 275 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Group 1: Olpasiran 10 mg Q12W | Group 2: Olpasiran 75 mg Q12W | Group 3: Olpasiran 225 mg Q12W | Group 4: Olpasiran 225 mg Q24W | Group 5: Placebo Q12W | Total |
|---|---|---|---|---|---|---|
| Asian | 6 | 5 | 5 | 5 | 3 | 24 |
| Black or African American | 0 | 1 | 2 | 1 | 2 | 6 |
| White | 52 | 52 | 47 | 49 | 48 | 248 |
| Other | 0 | 0 | 2 | 0 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Jul 2020 to primary completion in Dec 2021, 16 months.
Results were first posted in Aug 2023, 1 year 7 months after primary completion. A results delay was requested in Oct 2022.
Of 84 phase 2 interventional studies under Cardiovascular Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's 16 months is below that.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olpasiran